A.M. Kukanova^1,2, A.T. Bekisheva^1,3, N.M. Dhantemirova^1,3, M.S. Mauletbayev^1,3, D.N. Akhmedin^1,3, A.K. Makishev^1,3

1. «Astana Medical University» NCJSC, Astana, the Republic of Kazakhstan;
2. «National Laboratory Astana» PI, Astana, the Republic of Kazakhstan;
3. «Multidisciplinary Medical Center» SME on REM, Astana, the Republic of Kazakhstan

DOI: https://www.doi.org/10.52532/2521-6414-2024-1-71-30-34

UDC: 616.34-006.6:575.224.2

Year: 2024 issure: 71 number: 1 pages: 30-34

Download PDF:

ABSTRACT

Relevance: Colorectal cancer (CRC), arising from the right-sided or left-sided colon, is a separate clinical and pathological unit. The status of KRAS and its predictive value in CRC remain controversial.
The study aimed to explore the effect of primary tumor localization on KRAS gene status in CRC.
Methods: The study included 60 patients with colon and rectal cancer. The KRAS mutation test was performed on paraffin-coated tumor samples using PCR methods. Colon cancer was divided into right-sided colon cancer (RSCC) and left-sided colon cancer (LSCC).
Results: KRAS mutation was found much more often in rectal cancer (RC) and sigmoid colon (SC) (p=0.413) than in tumors in other parts of the colon. A combined analysis of our data and previously published data showed that KRAS mutation was more common in PSTC, especially in the area of the hepatic bend of the colon than in LSTC (p=0.120). The association of the KRAS mutation with the patient’s age (p<0.012) and the duration of hospitalization (p<0.001) was established.>
Conclusion: Our study revealed no significant difference in the KRAS status between colon cancer and rectal cancer. However, KRAS mutation was much more common in RSCC compared to LSCC. Patients with RSCC with mutated KRAS also had a worse prognosis and required longer hospitalization compared to wild-type KRAS. However, patients with LSCC did not demonstrate a similar effect.
Keywords: colon cancer, rectal cancer, sigmoid cancer, KRAS mutation.

List of sources used:

1. International Agency for Research on Cancer. Cancer TODAY. Age-Standardized Rate (World) per 100 000, Incidence and Mortality, Both sexes, in 2022 (Top 15 cancer sites) https://gco.iarc.fr/today/en/dataviz/bars?mode=cancer&group_populations=1&types=0_1&sort_by=value1. 08.02.2024.
2. National Cancer Institute. Cancer Stat Facts: Colorectal Cancer https://seer.cancer.gov/statfacts/html/colorect.html. 24.02.2024.
3. Stintzing S., Tejpar S., Gibbs P., Thiebach L., Lenz H.J. Understanding the role of primary tumour localisation in colorectal cancer treatment and outcomes // Eur. J. Cancer. – 2017. – Vol. 84. – P. 69-80. https://doi.org/10.1016/j.ejca.2017.07.016
4. Samatkyzy, D., Rakhimova, S., Begimbetova, D., Kukanova, A., Fazyl, F., Stefanov, I., Pirozhenko, O., Gabdulkayum, A., Kozhamkulov, U., Makishev, A., Tuleutayev, M., Akilzhanova, A., & Sarbassov, D. Evaluation of the KRAS mutations in colorectal and pancreatic cancer patients // Euras. J. Appl. Biotechnol. – 2022. – Vol. 4. – P. 99-110. https://doi.org/10.11134/btp.4.2022.13
5. Monedeiro F., Monedeiro-Milanowski M., Ligor T., Buszewski B. A Review of GC-Based Analysis of Non-Invasive Biomarkers of Colorectal Cancer and Related Pathways // J. Clin. Med. – 2020. – Vol. 9(10). – P. 3191. https://doi.org/10.3390/jcm9103191
6. Chiu J.W., Krzyzanowska M.K., Serra S., Knox J.J., Dhani N.C., Mackay H., Hedley D., Moore M., Liu G., Burkes R.L., Brezden-Masley C., Roehrl M.H., Craddock K.J., Tsao M.S., Zhang T., Yu C., Kamel-Reid S., Siu L.L., Bedard P.L., Chen E.X. Molecular Profiling of Patients With Advanced Colorectal Cancer: Princess Margaret Cancer Centre Experience // Clin. Colorectal Cancer. – 2018. – Vol. 17(1). – P. 73-79. https://doi.org/10.1016/j.clcc.2017.10.010
7. Cushman-Vokoun A.M., Stover D.G., Zhao Z., Koehler E.A., Berlin J.D., Vnencak-Jones C.L. Clinical utility of KRAS and BRAF mutations in a cohort of patients with colorectal neoplasms submitted for microsatellite instability testing // Clin. Colorectal Cancer. – 2013. Vol. 12(3). – P. 168-178. https://doi.org/10.1016/j.clcc.2013.04.005
8. Natsume S., Yamaguchi T., Takao M., Iijima T., Wakaume R., Takahashi K., Matsumoto H., Nakano D., Horiguchi S.I., Koizumi K., Miyaki M. Clinicopathological and molecular differences between right-sided and left-sided colorectal cancer in Japanese patients // Jpn. J. Clin. Oncol. – 2018. – Vol. 48(7). – P. 609-618. https://doi.org/10.1093/jjco/hyy069
9. Yahagi M., Okabayashi K., Hasegawa H., Tsuruta M., Kitagawa Y. The Worse Prognosis of Right-Sided Compared with Left-Sided Colon Cancers: a Systematic Review and Meta-analysis // J. Gastrointest. Surg. – 2016. – Vol. 20(3). – P. 648-655. https://doi.org/10.1007/s11605-015-3026-6
10. Gonçalves C., Duarte L., Alves J.J.C. Differences Between Right and Left Colon Cancer in Beira Interior // Cureus. – 2023. – Vol. 15(4). – Art. no. 37500. https://doi.org/10.7759/cureus.37500
11. Greco L., Rubbino F., Dal Buono A., Laghi L. Microsatellite Instability and Immune Response: From Microenvironment Features to Therapeutic Actionability-Lessons from Colorectal Cancer // Genes (Basel). – 2023. – Vol. 27(6). – Art. no. 1169. https://doi.org/10.3390/genes14061169
12. Tong J.H., Lung R.W., Sin F.M., Law P.P., Kang W., Chan A.W., Ma B.B., Mak T.W., Ng S.S., To K.F. Characterization of rare transforming KRAS mutations in sporadic colorectal cancer // Cancer Biol. Ther. – 2014. – Vol. 15(6). – P. 768-776. https://doi.org/10.4161/cbt.28550
13. Bteich F., Mohammadi M., Li T., Bhat M.A., Sofianidi A., Wei N., Kuang C. Targeting KRAS in Colorectal Cancer: A Bench to Bedside Review // Int. J. Mol. Sci. – 2023. – Vol. 27(15). – Art. no. 12030. https://doi.org/10.3390/ijms241512030
14. van der Kruijssen D.E.W., van der Kuil A.J.S., Vink G.R., Punt C.J.A., de Wilt J.H.W., Elias S.G., Koopman M. Time-varying prognostic value of primary tumor sidedness in metastatic colorectal cancer: A population-based study and meta-analysis // Int. J. Cancer. – 2023. – Vol.1(7). – P. 1360-1369. https://doi.org/10.1002/ijc.34347